The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products.
Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company.
